
    
      IMMUWHY Phase II Clinical Trial will test the Addition of the immunotherapeutic agents
      Durvalumab and Tremelimumab after an initial Standard of Care SIRT in patients suffering from
      non-resectable intrahepatic Biliary Tract Cancer. Patients will be randomized into two
      experimental arms, one receiving Durvalumab only, the other one receiving Durvalumab +
      Tremelimumab. Clinical Outcomes will be compared vs. historical datasets.
    
  